RecruitingEarly Phase 1NCT06775912

Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases

Studying Systemic sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Nanjing Bioheng Biotech Co., Ltd.
Intervention
RD06-05 CART Cell Injection(drug)
Enrollment
18 enrolled
Eligibility
18-70 years · All sexes
Timeline
20252027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06775912 on ClinicalTrials.gov

Other trials for Systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Systemic sclerosis

← Back to all trials